Overview

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Status:
Active, not recruiting

Trial end date:
2021-04-15

Target enrollment:

Participant gender:

Summary

The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Oncologico del Nord-Ovest

Collaborator:

Roche Pharma AG

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin